Organic Active Ingredients TRIZ Cases

AAV9 delivers an SRSF1 antagonist to neuronal cells, aiming to limit neurotoxicity while protecting against degeneration in sporadic ALS.

Bifunctional PROTACs recruit SMARCA2 to VHL for ubiquitination and degradation, addressing hard-to-bind cancer targets.

Selective benzyltryptamines target 5-HT2A while avoiding 5-HT2B activation, preserving CNS efficacy with lower cardiac risk.

Selective activation of TRPA1- or CGRP-linked vagal and brainstem neurons shifts cytokines to control immune responses in disease.

Targets PI3K-AKT-mTOR somatic mutations with mTOR inhibitors to reduce seizures and abnormal neuron generation in intractable epilepsy.

Specific excipient combinations lower viscosity in concentrated nucleic acid formulations, easing injection and processing while preserving stability.

Pressing cannabis biomass with edible oil enables solvent-free extraction, then carbon black purification removes contaminants while preserving cannabinoids and terpenes.

Novel N-desmethyl ruboxistaurin L-lactate polymorphs improve solubility and stability while reducing CYP3A4 metabolism and QT risk.

Direct ERK targeting with azaindole derivatives helps suppress tumor growth while avoiding the ERK reactivation that drives RAF and MEK inhibitor resistance.

Machine learning adapts opioid dose reduction to withdrawal, anxiety, and side effects, improving tapering support with personalized glide paths.

Ionizable stealth LNPs extend circulation while targeting T, B, and NK cells for safer, more efficient nucleic acid delivery.

Compounds recruit ubiquitination and proteasomal degradation to remove resistant EGFR mutants such as T790M, L858R, and C797S.

Adding hydroxycitric acid during T cell culture improves persistence and antitumor activity while reducing apoptosis for cancer therapy.

Vision sensors and AI quantify outdoor ad exposure, viewing duration, and attention in real time to improve campaign measurement and targeting.

Combining Seralutinib with Sotatercept targets multiple PAH pathways to better reduce pulmonary pressure and right ventricular hypertrophy.

Deuterated gamma-carbolines combine 5-HT2A antagonism and mu-opioid partial agonism to extend OCD relief with fewer side effects.

A topical Udonitrectag gel or emulgel improves microcirculation and wound healing in diabetic ulcers where conventional care often fails.

Iodide shifts the iodine equilibrium during gamma sterilization, keeping dilute povidone-iodine sterile, effective, and ready to use.

Heterobifunctional CyTaCs bridge CCR2-expressing cells and exogenous antibodies to boost ADCC while improving selectivity, stability, and manufacturability.

Fine gepotidacin granules disperse in water within 3 minutes to improve swallowability, palatability, and dose uniformity.

Periodic INX-315 dosing and amorphous spray-dried dispersion lower Cmax/Cmin spikes while sustaining anti-cancer exposure and limiting side effects.

A 10-amino camptothecin scaffold improves solubility and stability while preserving cytotoxicity for low-immunogenic immunoconjugates.

Novel glutamatergic compounds aim to deliver antidepressant effects within hours while reducing the side effects seen with ketamine.

High-aspect ratio paclitaxel crystals anchored in a porous balloon substrate improve coating robustness and make local vascular drug release more consistent.

ITIH1 suppresses HCC by competitively binding ITGB1/ITGA5 and inhibiting integrin-FAK signaling, supporting new drug development.

A tetrahydrocurcumin and silymarin blend improves liver metabolism and function while reducing enzyme markers, inflammation, and apoptosis.

Topical copper agents boost lysyl oxidase to strengthen corneal collagen and stabilize keratoconus without invasive CXL.

Blocking Galectin-9 signaling with antibodies boosts T cell and cytokine responses, helping treat cancers resistant to PD-1 or CTLA-4 therapy.

A lecithin and guar gum oral powder lets ibuprofen be taken dry or with a little water, improving taste, mouthfeel, and adherence.

Controlled rapamycin dosing activates DARIC signaling while limiting CAR T cytokine toxicity, neurotoxicity, and T cell exhaustion.

A microneedle delivers drug and hydrogel push formulations into the suprachoroidal space to localize ocular therapy and limit off-target spread.

Spray-dried amorphous dispersions and solubilized formulations raise Compound (I) bioavailability while preserving stability for oral dosing.

Pyridazine and phthalazine derivatives inhibit NLRP3 while improving selectivity, supporting treatment of inflammatory and degenerative diseases.

HPBCD extracts membrane cholesterol to improve sickle cell red blood cell deformability while reducing hemolysis risk.

Defined 50-800 mg daily dosing keeps the active metabolite above therapeutic plasma levels to improve inflammatory bowel disease treatment.

Azabicycle derivatives target autotaxin binding regions to deliver potent inhibition for fibrotic, inflammatory, autoimmune, and cancer-related diseases.

Isolating and purifying CBD-C1 solves cannabis extract variability while preserving anticonvulsant activity for consistent epilepsy dosing.

S1P1 modulators address lupus treatment limits by reducing inflammation, improving kidney function, and lowering side-effect burden.

Oral fluorescent challenge molecules enable rapid, non-invasive gut barrier assessment without phlebotomy or specialized lab equipment.

Small-molecule sulfonamide derivatives block IgE-FcεRI binding to inhibit mast cell degranulation and histamine release in allergic disease.

A self-microemulsifying oral formulation uses surfactants and co-solvents to solubilize a hydrophobic ALK inhibitor while preserving stability.

A membrane-localized insulin receptor fragment activates signaling without repeated insulin dosing, helping avoid hypoglycemia in neurological treatment.

RISC-cleaving dsRNA lowers Serpinc1 so hemophilia bleeds can be managed with reduced factor or bypassing-agent doses.

Direct NLRP3 inhibition with 5-FUMCL reduces IL-1β, IL-6, and IL-18 while limiting off-target effects in inflammatory disease models.

A novel GalNAc-linked nucleic acid conjugate improves liver-cell uptake, in vivo stability, and gene silencing with low toxicity.

Low-molecular-weight cyclic phosphatidic acid derivatives offer a safe, cost-effective approach to slow dementia progression and ease symptoms.

A defined crystal form improves thermal stability, compressibility, and static control for pharmaceutical preparation and long-term storage.

Amorphous ramelteon dispersed in a sublingual film bypasses first-pass loss, dissolves within 1 minute, and improves bioavailability.

Non-covalent purine-pyrimidine dimer cations reduce oxidative stress and promote cell proliferation to improve repair and wound healing.

IN10018 reduces tumor fibrosis so monoclonal antibodies and antibody conjugates can penetrate stroma and reach higher tumor concentrations.

By increasing GPR37 membrane localization, idoxuridine analogs protect neurons from oxidative stress and neurotoxin damage in parkinsonism.

Diflunisal treats cancer cachexia by inhibiting COX enzymes to restore muscle mass and strength with fewer side effects.

Sulfide-containing ionizable lipids improve nucleic acid encapsulation and stable lipid nanoparticle delivery while reducing inflammation and off-target buildup.

Flow micromixing reassembles ferritin around siRNA or DNA under controlled pH to suppress aggregation and improve encapsulation yield.

A BER-mediated pairing of PARP inhibitors and dU analogs drives lethal DNA damage in p53-deficient tumors while wild-type p53 cells arrest and repair.

PLGA microspheres suspended in hyaluronic acid enable sustained pirfenidone release in joints to curb OA inflammation and progression.

A hyperbranched UV-cleavable PBAE condenses nucleic acids at lower mass ratios, then degrades after uptake to improve transfection and reduce cytotoxicity.

Charge-reversed starch nanoparticles attract to negatively charged carious lesions and retain calcium and fluoride for tooth remineralization.

A hypromellose-xanthan suspension balances stability, taste, and rapid ibuprofen and phenylephrine absorption for flu and cold relief.

HDAC6 inhibition preserves Miro1 K105 acetylation to sustain mitochondrial transport and membrane potential, supporting axon growth on inhibitory CNS substrates.

Intra-arterial nanoliposomes deliver bioactive lipids to no-reflow sites, stabilizing endothelial membranes and reducing infarct size.

An adjuvant that inhibits uridine phosphorylase helps protect mucosal tissue from radiation-induced mucositis and treatment disruption.

Combined antioxidants create oxidative balance to rapidly reduce diabetic neuropathic pain while limiting side effects from treatment.

ASGPR-targeted GalNAc siRNA improves liver-cell delivery and nuclease resistance, enabling sustained inhibition of HBV gene expression.

Built-in pH-responsive and endosomal disruption segments enable one-pot graft copolymers to load hydrophilic drugs and improve cytosolic delivery.

Akkermansia-derived strains, vesicles, and extracts target alopecia with hair-growth effects while avoiding the side effects of minoxidil and finasteride.

A larger cliché indentation enables complete transfer of volatile active agents onto adhesive TTS substrates while avoiding overflow, oxidation, and downtime.

PEG- and alkyl-modified CD4 mimic compounds bind gp120 to block HIV entry while improving half-life, solubility, and cytotoxicity.

A single 300 mg netupitant dose extends antiemetic protection to 480 hours, addressing ADC nausea and vomiting beyond 120 hours.

Targeted hyaluronic acid injections near posterior skull soft tissue attachments reduce migraine and tension headache frequency and severity with fewer side effects.

Kinase inhibitors such as PKC412 and PP2 alter keratin phosphorylation to reduce filament aggregation, improve adhesion, and limit EBS blistering.

A crystalline Form II of 9-ING-41 uses controlled crystallization to improve stability, solubility, and dissolution for pharmaceutical use.

A petrolatum-based PHMB topical composition suppresses IL-36, IL-31, and IL-4 cytokines to treat inflammatory skin disease without steroids or injections.

A nonionic surfactant and chromatography carrier lower endotoxin in animal tissue-derived proteoglycan while preserving molecular weight.

Magnetic pulses, succussion, and color-changing LED light raise HSA binding in autologous blood nosodes for more effective agent transport.

Selective deuterium substitution in benzimidazole MEK inhibitors extends half-life and reduces undesired metabolites.

Metal coordination complexes and light inactivate tumor cells to create a vaccine that improves antigen presentation and anti-tumor immunity.

Formula (1) miR-124 inducer compounds improve oral absorption and metabolic stability while preserving potent in vivo therapeutic activity.

Deuterium-substituted DMT mixtures extend psychedelic duration through altered pharmacokinetics, avoiding infusion protocols and MAOI co-therapy.

Formula (A) compounds inhibit glutaminyl cyclase while reducing hydrophobicity-linked side effects and preserving metabolic stability.

Controlled polymorphic forms improve cardiac myosin selectivity, stability, pharmacokinetics, and safety while limiting smooth muscle effects.

Combined GST-π and MRPL17 suppression induces strong cancer cell death while limiting normal cell inhibition and side effects.

Engineered miRNA seed and scramble sequences suppress multiple inflammatory mRNAs to reduce tissue damage with fewer side effects.

Replacing meta-cresol with phenylmethanol in maropitant citrate injection reduces pain and adverse reactions while preserving antimicrobial protection.

Targeting USP16 offers a disease-modifying osteoarthritis approach that reduces senescence and inflammation while restoring cartilage and joint function.

By recruiting E3 ligase to EZH2, this PROTAC compound drives selective protein degradation to address resistance in EZH2-related cancers.

mTOR inhibition lowers IFN-I in ANTXR1-high tumors, enabling Seneca Valley virus replication and stronger antitumor responses.

Modified trimetazidine shifts cardiac metabolism toward glucose oxidation and boosts mitochondrial ATP production to treat HFpEF.

Specific carboxamide-modified 2-arylthiazoles improve autophagy induction to support cellular survival and slow disease progression.

Amorphous enzalutamide with HPMCAS-MG or PVPVA improves solubility, dissolution stability, and oral absorption in a single daily dose.

Novel triazatricycle compounds block TLR7, TLR8, and TLR9 to suppress autoimmune inflammation with improved solubility, stability, and low cytotoxicity.

Sets impurity limits for Compound 1 and Compound 2 to keep deutetrabenazine compositions stable at room temperature over time.

A dual-action amide compound blocks both 5-HT2A and 5-HT7 receptors, reducing multi-drug complexity in neuropsychiatric treatment.

Novel LANCL2-binding compounds enable oral treatment of autoimmune, inflammatory, and diabetic conditions while reducing inflammation and improving insulin sensitivity.

Novel pimarane diterpenoids isolated from Icacina oliviformis leaves inhibit colon cancer cells more strongly than 5-fluorouracil.

Anchoring antigens and adjuvants on engineered extracellular vesicles boosts dendritic cell targeting and CD4+/CD8+ T cell responses.

A hydroalcoholic NES-testosterone gel lowers sperm concentration while keeping testosterone in the normal range with minimal side effects.

GA-rich 3′-UTR-targeting ASOs suppress peripheral Rab13 and Net1 translation to curb cancer cell migration without disrupting overall protein distribution.

Eaton's reagent in continuous flow replaces 250°C cyclization, cutting solvent recovery burden while enabling scalable, high-purity synthesis.

Small-molecule Formula (I) compounds inhibit NLRP3 while lowering hERG risk and improving pharmacokinetic and physical properties.

Undruggable Ras proteins are targeted through heterobifunctional ligands that recruit cyclophilin A and form an inhibitory ternary complex.

Sterilize ensifentrine particles at 100–220°C, then aseptically combine them with a sterile liquid vehicle to limit formulation degradation.

CRISPR-Cas vectors modulate inflammatory cytokine signaling and cell phenotype to slow disc degeneration linked to low back pain.

Defined crystal systems and XRPD peaks address purity and reproducibility challenges in 5-MeO-DALT pharmaceutical development.

HPLC purification removes dsRNA contaminants from IVT RNA while preserving ssRNA integrity and supporting therapeutic translation.

A dual GLS/GLS2 inhibitor lowers glutamate production from glutamine and suppresses tumor growth where GLS-selective therapy fails.

Removing competing ions from isotonic drug formulations supports faster delivery with lower current and shorter iontophoresis treatment.

Current filarial treatments can leave adult worms untreated and cause resistance or adverse reactions; these compounds selectively target L3/L4 worms.

Ethanol reflux and macroporous-resin chromatography produce an Acanthus glycoside extract that lowers liver injury markers and inflammation.

Fiber-like crystals and an aqueous phase form a self-lubricating oral dosage form that limits adhesion and makes swallowing easier.

Partial cholesterol-pathway inhibition accumulates Δ8,9-unsaturated sterols in OPCs to support oligodendrocyte generation and remyelination.

Viral small RNA suppresses FDPS so IPP accumulates to activate GD T cells while addressing bisphosphonate inflammation and poor bioavailability.

Multiple-vector CRISPR delivery can disrupt Cas and Cascade expression; one vector coordinates both for efficient target modification.

Tris buffering at pH 8.0–8.5 supports stable, higher-concentration furosemide for subcutaneous or intravenous administration.

TRPV1 inhibitors target a pathological ion-channel pathway to suppress cardiac hypertrophy and related ventricular remodeling.

RNAi lowers HBV gene expression and HBsAg before antibody treatment, helping restore immune control with lower antibody doses.

Antioxidants or oxygen scavengers prevent corticosteroid oxidation in aqueous eye drops, preserving pH during extended LDPE vial storage.

Conventional PRMT5 inhibitors can lack MTAP-deleted cell selectivity; MTA-uncompetitive compounds leverage accumulated MTA for targeted toxicity.

A modified 2-heteroaryl aminoquinazolinone compound targets neural circuit hyperexcitation while addressing narrow therapeutic range and side effects.

Water-soluble and swellable polymer matrices help oral films balance rapid dissolution with controlled active release and consistent delivery.

Halogenated clozapine targets D4 and 5HT2A receptors while minimizing D2, H1, and M4 interactions to reduce side effects.

ES2 blocks endosomal trafficking that moves ACE2 to immune-cell surfaces, reducing susceptibility to SARS-CoV-2 infection.

Chimpanzee adenovirus vectors deliver tumor-specific neoantigens while addressing pre-existing human immunity in vaccine design.

Targeting MSI2 with oligonucleotides or small molecules raises miR-7, normalizes autophagy, and may reduce muscle wasting in myotonic dystrophy.

Solvent reduction and extraction combined with esterification and MCT oil address betulinic acid bioavailability in Chaga-based formulations.

TAS2R agonists target airway smooth muscle receptors to relax human bronchi without β2-agonist cross-desensitization.

Phloroglucinol-based synthesis uses mild, selective conditions and telescoped steps to produce pure cannabinoids while limiting THC.

Deudomperidone uses targeted deuterium substitution to increase gastric emptying in gastroparesis while limiting blood-brain barrier penetration.

PM2.5 exposure can disrupt lung-cell energy supply; phosphocholine activates fatty acid oxidation to alleviate the resulting deficiency.

Chemotherapy can cause diarrhea and mucositis; intestinal alkaline phosphatase helps protect the GI tract while preserving cancer treatment efficacy.

Combining liquid and powder nasal parts strengthens mucoadhesion, slows clearance, and keeps therapeutic agents in contact with nasal mucosa longer.

Poor membrane entry limits siRNA delivery; perfluoroalkyl groups enable direct, reagent-free cellular uptake.

Apyrimidyl-substituted MEK inhibitors target MAPK/ERK reversal while addressing weak clinical efficacy and drug-related toxicity.

Mutant-selective compounds target PI3Kα-driven tumors while sparing wild-type PI3Kα linked to glucose homeostasis and hyperglycemia.

Transmucosal tablets, films, sprays, and gels bypass hepatic first-pass metabolism for rapid absorption and lower dosing needs.

High-viscosity HA stabilizes the tear film at low concentration, helping prevent severe ocular surface disease and preserve visual performance.

These compounds target myosin phosphate release to improve DCM contractility without prolonging systole or shortening diastole.

Deep-learning-guided target selection identifies small-molecule inhibitors that address aging pathways and reduce senescent cells.

Non-immunogenic mRNA encoding oxidoreductase–T-cell epitope fusion peptides induces cytolytic CD4+ T-cells to reduce autoimmune responses.

Combines opicapone, levodopa, and an AADC inhibitor to delay Parkinson’s progression while reducing OFF time without significantly increasing dyskinesia.

Cyclodextrin and starch stabilize cetirizine with polyols in a single-layer chewable tablet, addressing degradation and swallowing difficulty.

Low gastrointestinal absorption limits conventional mineral and vitamin products; sucrosomial solid forms use phospholipids and sucresters to improve bioavailability.

A pH-protected rifaximin–NAC formulation uses NAC’s mucolytic action to penetrate mucus and target bacteria in the small intestine.

Combining a thioether-linked antibody-drug conjugate with EZH1/EZH2 inhibitors creates synergistic antitumor activity across several cancers.

This case combines novel compounds with lifestyle intervention to address liver fat, inflammation, and fibrosis in NAFLD and NASH.

This case combines allosteric ALC1 inhibitors with PARP inhibitors to increase DNA damage and address resistance in BRCA-deficient tumors.

This case combines analgesia, AdipoR activation, and neuronal protection against hyperglycemia-induced apoptosis.

This case combines microcrystalline cellulose, calcium hydrogen phosphate, and wet granulation for stable ticagrelor release.

This ophthalmic suspension uses submicron particles and polymer-controlled gel rheology to extend residence without severe vision blurring.

This case combines acalabrutinib and capivasertib in defined schedules to improve cancer cell death and inhibit tumor growth.

Combining a CXCR2 agonist with a CXCR4 antagonist selectively enriches CD34+ cell purity while reducing graft-versus-host disease risks.

2-Phenylimidazo[1,2-a]pyrimidine radioligands cross the blood-brain barrier to bind tau aggregates with high affinity.

Direct amide bonds stabilize hyaluronic acid and carnosine conjugates, reducing lipid oxidation and toxicity in osteoarthritis treatment.

An in vitro method uses polymerase and protelomerase to produce closed linear DNA, avoiding bacterial contamination and reducing purification costs.

Segmented acyl-amino-LNA oligonucleotides resolve the trade-off between nuclease resistance and RNase H compatibility to achieve efficient gene silencing.

A modified compound incorporating a low-molecular polyethylene glycol fragment enhances water solubility and protein kinase G inhibitory activity.

Heterocyclic derivatives inhibit MALT1 to treat cancers and inflammatory disorders despite resistance challenges.

Combining testosterone undecanoate with a PPARα agonist reduces HDL suppression and cardiovascular risk while maintaining stable serum levels.

Segmenting apoptosis pathways into measurable biomarkers resolves identification difficulties to enhance treatment efficiency.

Novel acylhydrazone derivatives inhibit NF-kB and MAPK pathways, reducing epithelial hyperplasia without steroid resistance or side effects.

Diphenyloxyalkylamine derivatives inhibit respiratory smooth muscle contraction and pulmonary inflammation.

Azetidinyl pyrimidine compounds inhibit kinases to treat ocular inflammation while maintaining stability under varying environmental conditions.

A pyrimidine compound targets c-MET and RON kinases to reduce tumor metastasis.

A glucan gel product induces controlled inflammatory responses through a stable three-dimensional structure.

A preservative-free prochlorperazine nasal spray formulation enables rapid drug absorption through the nasal mucosa.

A sustained-release capsule formulation uses hydroxypropyl methylcellulose to control liothyronine release kinetics.

Stoichiometric control reduces phosphorus by-products while MTHF prevents product loss during aqueous work-up.

Macrocyclic compounds bind Ras and cyclophilin A to create a new binding pocket, addressing the lack of druggable sites on mutant Ras proteins.

Piperazine-1-carboxamidine addresses core autism symptoms like hyperactivity and lack of sociability, which existing drugs fail to treat.

Oral (6R)-2-amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole decreases mortality and increases life expectancy in definite ALS patients.

Low oxidized fish oil emulsion combined with acetylsalicylic acid stabilizes omega-3 delivery.

A voltage switch circuit uses low voltage transistors with a biasing mechanism to couple input terminals to an output terminal.

Substituted indolin-2-one derivatives target the p38 alpha isoform to reduce TNF-alpha production and minimize off-target side effects.

Heteroaromatic compounds target dopamine D1 receptors to treat cognitive symptoms, addressing limited efficacy and specificity of current agents.

Cyclodextrin inclusion complexes solubilize poorly water-soluble meloxicam, enabling rapid onset of pain relief in migraine patients.

Novel aromatic heterocyclic compounds act as antagonists at the 5-HT6 receptor to treat Alzheimer's disease.

Topical bases using pracaxi oil and breu-branco resin reduce systemic side effects from NSAIDs by lowering required API dosages through local delivery.

A food supplement combines cannabinoids with hydrolyzed collagen, hyaluronic acid, glucosamine, and ascorbic acid to support joint health.

A controlled release gel formulation delivers an OGFR antagonist via minimally invasive injection to sustain therapeutic levels at the tumor site.

Inhibiting pro-fibrotic signaling with small molecules enables rapid conversion of fibroblasts into beating cardiomyocytes.

Mandelic acid condensation polymers block pathogen attachment to reduce STD transmission risk without interfering with natural vaginal mechanisms.

Adaptor Associated Kinase 1 inhibitors block viral entry and replication to treat infections lacking effective therapies.

Strategic fluorine substitutions on amidine cores enhance blood-brain barrier permeability while maintaining potent BACE1 inhibitory activity.

Glucocorticoid receptor inhibitors block compensatory signaling pathways in prostate cancer cells.

Uridine phosphoramide prodrugs target the liver using ester-forming groups, reducing systemic toxicity while maintaining anti-HCV efficacy.

Solvent-mediated transformation yields a thermodynamically stable cabotegravir sodium polymorph that prevents phase transitions during storage.

Modifying cyclic carbocyclic groups and dihydroxyalkyl substituents balances nociceptin binding affinity with metabolic stability.